Get the Stockscreener App
7.05
0.14%
0.010
Kyntra Bio Inc stock is traded at $7.05, with a volume of 17,706.
It is up +0.14% in the last 24 hours and down -3.69% over the past month.
Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.
See More
Previous Close:
$7.04
Open:
$7.025
24h Volume:
17,706
Relative Volume:
1.02
Market Cap:
$28.54M
Revenue:
$7.44M
Net Income/Loss:
$-56.57M
P/E Ratio:
0.2567
EPS:
27.467
Net Cash Flow:
$-21.40M
1W Performance:
-3.03%
1M Performance:
-3.69%
6M Performance:
-5.37%
1Y Performance:
+0.00%
1-Day Range:
$6.9509
$7.4074
1-Week Range:
$6.91
$7.4074
52-Week Range:
$6.32
$9.58
Kyntra Bio Inc Stock (KYNB) Company Profile
Name
Kyntra Bio Inc
Sector
Industry
Phone
415-978-1200
Address
350 BAY STREET, SAN FRANCISCO
Compare KYNB vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KYNB
Kyntra Bio Inc
|
7.05 | 28.74M | 7.44M | -56.57M | -21.40M | 27.47 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Kyntra Bio Inc Stock (KYNB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-08-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-26-23 | Downgrade | BofA Securities | Buy → Neutral |
| Jun-26-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jun-26-23 | Downgrade | Stifel | Buy → Hold |
| Jun-26-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jun-02-23 | Upgrade | Stifel | Hold → Buy |
| Jan-31-23 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-26-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jan-05-23 | Upgrade | BofA Securities | Neutral → Buy |
| Sep-22-21 | Downgrade | Goldman | Neutral → Sell |
| Aug-20-21 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Jul-16-21 | Downgrade | BofA Securities | Buy → Neutral |
| Jul-16-21 | Downgrade | Stifel | Buy → Hold |
| Apr-07-21 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Apr-07-21 | Downgrade | Mizuho | Buy → Neutral |
| Mar-31-21 | Upgrade | BofA Securities | Neutral → Buy |
| Mar-02-21 | Downgrade | Jefferies | Buy → Hold |
| Feb-01-21 | Initiated | H.C. Wainwright | Buy |
| Oct-26-20 | Initiated | Raymond James | Underperform |
| Jul-10-20 | Resumed | Stifel | Buy |
View All
Kyntra Bio Inc Stock (KYNB) Latest News
Kyntra Bio Confronts Nasdaq Listing Risk as Asset and Revenue Shortfall Threatens Global Select Status - TipRanks
Kyntra Bio, Inc. (NASDAQ: KYNB) Stock Price, News & Analysis - kalkine.ca
Armistice Capital (KYNB) discloses 400,000-share, 9.88% Kyntra Bio position - Stock Titan
Kyntra Bio Inc Q2 Net Income From Cont Ops US - Moomoo
KYNB Looks 28.4% Overvalued on GF Value™ - GuruFocus
Kyntra Bio: Q2 Earnings Snapshot - AOL.com
Kyntra Bio Q2 adj. EPS $(4.68) misses $(3.18) estimate - scanx.trade
Kyntra Bio Q2 2026 slides: dual catalysts expected, cash into 2028 - Investing.com
Kyntra Bio Q2 2026 slides: prostate cancer, MDS programs eye Q4 catalysts - Investing.com
Earnings call transcript: Kyntra Bio rises as pipeline updates offset weak Q2 2026 sales - Investing.com
Kyntra Bio Q2 2026 Earnings Call: Complete Transcript - benzinga.com
KYNB: Q2 2026 marked clinical progress and a return to profitability, with cash runway into 2028 - TradingView
Kyntra Bio (KYNB) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Kyntra Bio, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
KYNTRA BIO ($KYNB) Releases Q2 2026 Earnings - quiverquant.com
Is Kyntra Bio Inc (KYNB) Facing Challenges After Q2 Earnings Mis - GuruFocus
Kyntra Bio (Nasdaq: KYNB) turns Q2 profit as deconsolidation gain offsets cash burn - Stock Titan
Kyntra Bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Kyntra Bio Targets Late-2026 Milestones for Cancer and Anemia Drugs - Stock Titan
Kyntra Bio Reports Second Quarter 2026 Financial Results and Provides Business Update - GlobeNewswire
Kyntra Bio, Inc. expected to post a loss of $3.18 a shareEarnings Preview - TradingView
Earnings Preview: Kyntra Bio to Report Financial Results Post-market on August 13 - 富途牛牛
Kyntra Bio to Report Second Quarter 2026 Financial Results - GlobeNewswire
Kyntra Bio (KYNB) Expected to Beat Earnings Estimates: Should You Buy? - Yahoo Finance
KYNB Q2'26 Earnings: revenue estimate is 2.09M USD - TradingView
Kyntra Bio (KYNB) Holds Steady at $6.79 as Consolidation Builds Toward Key $7.13 TestCall Resistance - dars.gov.et
Kyntra Bio Inc. (KYNB) Holds Steady at $7.0 as Traders Eye Key LevelsAdvance Decline Line - dars.gov.et
Kyntra Bio, Inc. Revenue Breakdown – NASDAQ:KYNB - TradingView
Kyntra Bio, Inc. (KYNB) Q4 2024 Earnings ReportResults, Call & Slides - TipRanks
Kyntra Bio, Inc. (KYNB) Q1 2025 Earnings ReportResults, Call & Slides - TipRanks
Kyntra Bio, Inc. (KYNB) Q3 2025 Earnings ReportResults, Call & Slides - TipRanks
Kyntra Bio, Inc. (KYNB) Q2 2025 Earnings ReportResults, Call & Slides - TipRanks
Kyntra Bio, Inc. (KYNB) Q2 2024 Earnings ReportResults, Call & Slides - TipRanks
Kyntra Bio, Inc. (KYNB) Q1 2024 Earnings ReportResults, Call & Slides - TipRanks
Kyntra Bio, Inc. (KYNB) Q3 2024 Earnings ReportResults, Call & Slides - TipRanks
KYNB Stock | Kyntra Bio, Inc. Price, Quote, News & Analysis - TipRanks
Kyntra Bio (KYNB) Shows Strength: Biotech Stock Advances 2.5% as Key Levels Come into PlayDeath Cross - dars.gov.et
Kyntra Bio Inc. (KYNB) Sheds 1.5% as Shares Test Key Support ZoneCounter Trend Trade - dars.gov.et
If You Invested $1,000 in KYNTRA BIO INC (KYNB) - Stock Titan
Oppenheimer Maintains Kyntra Bio(KYNB.US) With Buy Rating, Maintains Target Price $35 - Moomoo
Oppenheimer Initiates Kyntra Bio(KYNB.US) With Buy Rating, Announces Target Price $35 - Moomoo
KYNB Initiated Coverage by Oppenheimer -- Rating Set to Outperfo - GuruFocus
Oppenheimer initiates Kyntra Bio stock coverage with outperform rating - Investing.com UK
Oppenheimer initiates Kyntra Bio stock coverage with outperform rating By Investing.com - Investing.com Nigeria
Kyntra Bio Inc. (KYNB) Slides 1.97% as Stock Tests Key Support Near $7.11Time Weighted Price - dars.gov.et
Net margin % of Kyntra Bio, Inc. – DUS:1FG0 - TradingView
Kyntra Bio Inc. (KYNB) Edges Higher as Shares Approach Resistance at $8.01Dynamic Hedging - dars.gov.et
KYNB Q1 2026 Earnings: EPS Misses Estimates as Clinical-Stage Biotech Advances PipelineShort-Term Outlook - dars.gov.et
FibroGen stock rises after announcing rebrand to Kyntra Bio By Investing.com - Investing.com Nigeria
Enterprise value to revenue forward of Kyntra Bio, Inc. – DUS:1FG0 - TradingView
Enterprise value to EBITDA forward of Kyntra Bio, Inc. – DUS:1FG0 - TradingView
Kyntra Bio Inc Stock (KYNB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):